WINDLAS · NSE
Windlas Biotech Limited
₹1,109.45
-0.73% (-₹8.15)
Prev. close
₹1,117.6
Volume
71,125
Delivery %
52.5%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Windlas Biotech Limited
Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable and dispersible tablets, customized generics, and complex generics and multi-drug combinations, as well as injectables, including liquid vials, lyophilized vials, and ampoules. In addition, the company offers generic drugs for respiratory, anti-diabetic, gastroenterology, cardiovascular and multivitamin, neuro anti-psychotic, diabetic care, nutraceuticals, nutritional supplement, urology, pain management, and injectable therapies. It also exports generic medicines, health supplements, and custom-branded formulations. The company sells generic medicines, health supplements, and custom-branded formulations under Windlas brand names. Windlas Biotech Limited was incorporated in 2001 and is headquartered in Dehradun, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Ms. Komal Gupta
Headquarters
Dehradun
Employees
1,385
Website
windlas.comExchange
View on NSE ↗Key stats
Market cap
₹2,289.49 Cr
P/E ratio (TTM)
35.6
Dividend yield
0.59%
EPS (TTM)
₹31.18
Beta (1Y · daily vs NIFTY 50)
0.72
Beta (5Y · monthly vs NIFTY 50)
0.68
Shares float
72.73 L
EPS · quarter ended Jun 2026
₹8.32
Financial Performance
01 · Financials
FY22 growth needs FY21 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ₹465.93 Cr | ₹513.08 Cr | ₹630.96 Cr | ₹759.88 Cr | ₹904.09 Cr | |
| EBITDA | ₹59.13 Cr | ₹70.19 Cr | ₹91.64 Cr | ₹112.13 Cr | ₹122.55 Cr |
| ₹38.09 Cr | ₹42.63 Cr | ₹58.19 Cr | ₹60.99 Cr | ₹66.46 Cr | |
| Diluted EPS | ₹18.8 | ₹19.7 | ₹27.88 | ₹28.87 | ₹31.15 |
09 · Balance Sheet
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹528.98 Cr | ₹626.21 Cr | ₹760.45 Cr | ₹907.35 Cr | |
| — | ₹4.99 Cr | ₹3.64 Cr | ₹32.60 Cr | ₹35.24 Cr | |
| Stockholders' equity | — | ₹402.27 Cr | ₹449.94 Cr | ₹505.77 Cr | ₹580.84 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, CWIP, Others, Total debt, Current (short-term) debt, Stockholders' equity have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ₹9.13 Cr | ₹60.97 Cr | ₹108.96 Cr | ₹68.19 Cr | ₹104.93 Cr | |
| Investing cash flow | ₹-154.58 Cr | ₹-14.11 Cr | ₹-92.07 Cr | ₹-74.06 Cr | ₹-91.79 Cr |
| ₹130.09 Cr | ₹-43.74 Cr | ₹-15.29 Cr | ₹1.01 Cr | ₹-13.03 Cr | |
| Capital expenditure | ₹-14.80 Cr | ₹-70.89 Cr | ₹-37.68 Cr | ₹-52.19 Cr | ₹-67.66 Cr |
| End cash position | ₹57.00 L | ₹3.69 Cr | ₹5.29 Cr | ₹42.40 L | ₹53.50 L |
Debt repaid has filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Sep 22(5Q) | Dec 22 | Feb 23 | Mar 23 | Apr 23 | Jun 23–Mar 24(4Q) | Jun 24–Dec 24(3Q) | Mar 25–Jun 25(2Q) | Sep 25–Dec 25(2Q) | Mar 26 | May 26–Jun 26(2Q) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 59.95% | 60.75% | 61.22% | 62.38% | 62.44% | 62.82% | 62.51% | 62.34% | 61.99% | 61.90% | 63.31% |
| Public | 40.05% | 39.25% | 38.78% | 37.62% | 37.56% | 37.18% | 37.49% | 37.66% | 38.01% | 38.10% | 36.69% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Windlas Biotech Limited | ₹2,289.49 Cr | ₹1,109.45 | 35.6 | 3.94 | 11.4% | 0.06 | +18.9% | +16.2% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Annual reports
Concall transcripts
Show all 12
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
2 indices
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.